Luna Innovations Incorporated (NASDAQ:LUNA) today announced its
financial results for its second quarter ended June 30, 2007. As
compared to the same quarter last year, revenues grew by 59%, from
$4.9 million to $7.9 million, gross profit increased from $1.4
million to $2.9 million, and the loss per share declined from $0.37
to $0.21. Kent Murphy, Chairman and Chief Executive Officer,
provided this overview: �While we are still in the early stages of
realizing a return on our investments in the product side of our
business, those investments are being validated by strong financial
trends, including increasing revenues, substantially improved
margins and more efficient cash usage, as well as the achievement
of significant operating milestones. Our technology portfolio and
contracts for additional development opportunities continue to
expand - as do the product sales and licensing transactions that
emerge from those contracts. The high-growth, higher-margin product
and license revenues are becoming a larger percentage of our total
revenues, increasing from 15% of total revenues in the second
quarter of 2006 to 25% in this year�s second quarter. Product and
license sales increased year-over-year by 163%, from $762,442 to
$2.0 million, driving gross profit, as a percentage of revenue,
from 29% in the second quarter of 2006 to 37% in our most recent
quarter.� Murphy added, �We also achieved two important milestones
in medical devices this past quarter. The first was the Food and
Drug Administration (FDA) clearance of our emboli detection and
classification system, the EDAC� QUANTIFIER, and second was the
signing of a multi-year intellectual property licensing,
development and supply agreement with Intuitive Surgical, the world
leader in robotic-assisted minimally invasive surgery (MIS). �Now
that the EDAC QUANTIFIER has received FDA clearance, we are
pursuing our next steps for the device, which include certification
of its manufacturing process so that it can be deployed in a
clinical environment in the United States, and entering into a
strategic marketing agreement with a third party distributor for
the device. �Another important event was the announcement of our
partnership with Intuitive Surgical. Upon successful completion of
the multi-year development effort, Intuitive intends to integrate
Luna�s shape sensing technology into its product line, which
includes the da Vinci� Surgical System. Intuitive plans to broaden
the application of its MIS approach to an expanding range of
procedures, which represents a great, long-term growth opportunity
for Luna. �In addition to medical devices, we are also developing
nanotechnology that has potential pharmaceutical applications. In
partnership with Virginia Commonwealth University, we have shown
that carbon nanospheres are capable of blocking the allergic
response in both human cell culture experiments and in mice.
Although this technology is still in the early stages of
development, we believe this discovery could potentially lead to
new therapies for allergies using nanomaterials and the creation of
an entirely new field of medicine we are calling nanoImmunology. In
keeping with our business model, we intend to seek strategic
partners to help further these developments.� Second Quarter
Financial Highlights Total revenues for the second quarter of 2007
increased 59% compared to the second quarter of 2006. Product
revenues represented over 25% of total revenues in the second
quarter of 2007, compared to 15% in the second quarter of 2006.
Product revenues grew 163% to approximately $2.0 million in the
second quarter of 2007, compared to $762,442 in the second quarter
of 2006. Gross profit for the second quarter of 2007 increased to
$2.9 million, or 37% of revenues, from $1.4 million, or 29% of
revenues, for the corresponding period of 2006. While operating
expenses grew compared to last year, operating expenses as a
percentage of revenue decreased from 86% in the second quarter of
2006, to 66% in the second quarter of 2007, and have remained
consistent at a range of $5.2 million to $5.4 million for each of
the past three quarters. The company reported a loss per share for
the second quarter of 2007 of $0.21 per share, compared to a loss
per share of $0.37 for the second quarter of 2006. On a sequential
basis, the company�s cash and cash equivalents increased to
approximately $13,933,000 at June 30, 2007, compared to
approximately $13,889,000 at March 31, 2007. Cash flows for the
second quarter included approximately $338,000 cash provided by
operating activities, $472,000 cash used in investing activities,
and $178,000 cash provided by financing activities. Cash flows from
operating activities also included an increase of approximately
$1.4 million in deferred revenues during the quarter. Business
Highlights Technology Development Reinforced leadership position in
harsh environment sensors by winning a $2.1 million contract with a
U.S. government agency for the development of sensors and
electronics that have the potential to be deployed in future
transport vehicles and nuclear power plants. Awarded $1.6 million
in continuation contracts for development of potential nanomaterial
photonic applications, including increased solar cell efficiency,
development of higher-speed telecommunication devices, and more
sensitive medical diagnostic equipment. Published a paper in
collaboration with Virginia Commonwealth University in the July 1,
2007, issue of the Journal of Immunology. The study is the first to
demonstrate that carbon nanospheres are capable of blocking
allergic response in human cell culture experiments and mice,
setting the stage for the development of new potential therapies
for allergies using nanomaterials. According to the Asthma and
Allergy Foundation of America, allergy is the fifth leading chronic
disease in the United States among all ages, and the third most
common chronic disease among children under 18 years old.
Healthcare Products Received FDA clearance to market the EDAC
QUANTIFER for clinical use in the United States. Entered into a
development and supply agreement with Intuitive Surgical, Inc.
Under the terms of the multi-year agreement, Luna has agreed to
develop and supply its fiber optic-based shape sensing and position
tracking system for integration into Intuitive Surgical�s products,
which includes the da Vinci� Surgical System. Instrumentation, Test
& Measurement Products Booked twice as much business as
compared to the same quarter of 2006 � receiving orders for more
than $2.0 million and recognizing $1.2 million of revenues from
shipment of optical instrumentation, test and measurement products.
Received the largest order in the history of the company�s Luna
Technologies division for multiple Optical Vector Analyzer systems.
The purchase allows an optical components manufacturer to replace
multiple test stands with a single Luna instrument and is estimated
by the customer to reduce their cost of testing by over 80%.
Outlook for Fiscal Year 2007 The company reiterates its guidance
for continued strong growth in both its product and technology
development divisions for the remainder of 2007. For fiscal year
2007, the company expects total revenue to be in the range of $30.0
million to $32.0 million, consisting of product and license revenue
of $7.0 to $8.0 million and technology development revenue of $23.0
to $24.0 million. For the full year 2007, the company anticipates a
net loss in the range of $9.0 to $9.5 million. For the third
quarter of 2007, the company expects revenue of approximately $8.7
million and a net loss of approximately $2.3 million. The company
plans to discuss its third quarter and fiscal year 2007 guidance on
its investor conference call to be held later today. Conference
Call Information As previously announced, Luna Innovations will
conduct an investor conference call at 5:00 p.m. (EDT) today to
discuss its second quarter financial results and expectations for
the remainder of 2007. The call can be accessed by dialing
1.866.770.7146 domestically or 1.617.213.8068 internationally prior
to the start of the call. The access code is 99587972. The
conference call will also be webcast live over the Internet. The
webcast can be accessed by logging on to the �Investor Relations�
section of the Luna Innovations website,
http://www.lunainnovations.com, prior to the event. The webcast
will be archived under the �Webcasts and Presentations� section of
the Luna Innovations website for at least 30 days following the
conference call. About Luna Innovations Luna Innovations
Incorporated develops and manufactures new-generation products for
the healthcare, telecommunications, energy and defense markets. Our
products are used to measure, monitor, protect and improve critical
processes in the markets we serve. Through its disciplined
commercialization business model, Luna has become a recognized
leader in transitioning science to solutions. Luna is headquartered
in Roanoke, Virginia. Additional information can be found at
www.lunainnovations.com. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995 This press release
includes information that constitutes �forward-looking statements�
made pursuant to the safe harbor provision of the Private
Securities Litigation Reform Act of 1995, including but not limited
to statements regarding, (i) expected realization of a return on
investment in the company�s products, (ii) continued expansion of
Luna�s technology portfolio and contracts for additional
development opportunities; (iii) continued growth in higher-margin
product and license revenues, (iv) the company�s plans to obtain
certification for its EDAC product manufacturing process and
entering into a strategic marketing agreement with a third-party
distributor, (v) Intuitive�s plans to integrate Luna�s shape
sensing technology into its product line pending successful
completion of the multi-year development agreement, (vi) potential
pharmaceutical applications for the company�s nanotechnology,
including new potential therapies for allergies using nanomaterials
and the creation of an entirely new field of medicine, (vii) the
company�s plans to seek strategic partners to help further
development of nanomaterial pharmaceuticals applications, (viii)
potential deployment of the company�s sensor and electronic
products in future transport vehicles and nuclear power plants,
(ix) potential nanomaterial photonic applications, including
increased solar cell efficiency, development of higher-speed
telecommunication devices, and more sensitive medical diagnostic
equipment, (x) the company�s guidance for continued strong growth
in the both the product and technology development divisions for
the remainder of 2007, and (xi) revenue and net loss guidance for
the third quarter and full year 2007. The company attempts,
whenever possible, to identify forward-looking statements by words
such as �intends,� �will,� �plans,� �anticipates,� �expects,�
�may,� �estimates,� �believes,� �should,� �projects,� or
�continue,� or the negative of those words and other comparable
words. Similarly, statements that describe the company�s business
strategy, goals, prospects, opportunities, outlook, objectives,
plans or intentions are also forward-looking statements. Actual
events or results may differ materially from the expectations
expressed in such forward-looking statements as a result of various
factors, including risks and uncertainties, many of which are
beyond the company�s control. Factors that could cause actual
results to differ materially from the expectations expressed in
such forward-looking statements include, but are not limited to:
the company�s ability to manage its growth effectively; the
company�s ability to transition its revenue mix from technology
development revenues to product and licensing revenues; the
company�s ability to successfully identify market needs for new
products; the risk that company�s proprietary rights may be
insufficient to protect its technologies, including potential
claims by third parties that the company infringes their
intellectual property rights; the company�s continued reliance on
contract research, including government grants and contracts
available only to small businesses, for a significant portion of
its revenue; the risk that the company may become ineligible for
small business government grants and contracts in the future; the
effect of competition in its markets and changes in customer
demand; the potential impact of federal audits and investigations;
delay in obtaining clearance by the U.S. Food and Drug
Administration or meeting other regulatory requirements, and
failure to comply fully with such regulations; the company�s
ability to secure third-party reimbursement for its healthcare
products; continued difficulty in, or increased costs related to,
hiring, training and retaining skilled employees; unanticipated
manufacturing or supply problems; the potential for the company�s
nanotechnology products to be perceived as harmful; a slowdown in
the overall economy; and uncertainty in the global political
environment. Additional factors that may affect the future results
of the company are set forth in its annual and quarterly reports on
Form 10-K and Form 10-Q, respectively, and other filings with the
Securities and Exchange Commission (�SEC�), which are available at
the SEC�s website at http://www.sec.gov, and at Luna Innovations�
website at http://www.lunainnovations.com. These risk factors are
updated from time to time through the filing of periodic reports
with the SEC. The statements made in this press release are based
on information available to the company as of the date of this
release and Luna Innovations undertakes no obligation to update any
of the forward-looking statements herein after the date of this
press release. Luna Innovations Incorporated Consolidated
Statements of Operations � � Three Months Ended Six Months Ended �
June 30, June 30, 2007 � � 2006 � � 2007 � � 2006 � � (unaudited)
(unaudited) (unaudited) (unaudited) Revenues: Contract research
revenues $ 5,852,109 $ 4,170,273 $ 11,138,706 $ 8,091,212 Product
and license revenues 2,003,171 � � 762,442 � � 3,786,747 � �
1,357,740 � Total revenues 7,855,280 4,932,715 14,925,453 9,448,952
Cost of revenues: Contract research costs 4,048,424 3,105,289
7,898,039 6,013,124 Product and license costs 911,768 � � 408,219 �
� 1,712,189 � � 674,270 � Total cost of revenues 4,960,192 � �
3,513,508 � � 9,610,228 � � 6,687,394 � Gross Profit 2,895,088
1,419,207 5,315,225 2,761,558 Operating expense 5,185,965 � �
4,252,343 � � 10,400,984 � � 7,694,351 � Operating loss (2,290,877
) � (2,833,136 ) � (5,085,759 ) � (4,932,793 ) Other income
(expense) Other income � - 3,110 519 9,397 Interest income, net
113,107 � � 109,185 � � 225,375 � � 113,145 � Total other income
113,107 � � 112,295 � � 225,894 � � 122,542 � Loss before income
taxes (2,177,770 ) (2,720,841 ) (4,859,865 ) (4,810,251 ) Income
tax expense - � � - � � - � � - � Net loss $ (2,177,770 ) $
(2,720,841 ) $ (4,859,865 ) $ (4,810,251 ) Net loss per share:
Basic $ (0.21 ) $ (0.37 ) $ (0.48 ) $ (0.72 ) Diluted $ (0.21 ) $
(0.37 ) $ (0.48 ) $ (0.72 ) Weighted average shares: Basic
10,136,446 � � 7,277,964 � � 10,053,371 � � 6,677,306 � Diluted
10,136,446 � � 7,277,964 � � 10,053,371 � � 6,677,306 � Luna
Innovations Incorporated Consolidated Balance Sheets � June 30,
December 31, � 2007 � � 2006 � � Assets (unaudited) Current assets
Cash and cash equivalents $ 13,933,115 $ 17,866,753 Accounts
receivable, net 7,999,979 7,233,406 Refundable income taxes 396,062
396,062 Inventory 1,334,619 843,294 Other current assets � 447,039
� � 503,703 � Total current assets 24,110,814 26,843,218 Property
and equipment, net 6,271,336 5,730,094 Intangible assets, net
1,965,947 2,031,489 Deferred tax asset 600,000 600,000 Other assets
� 12,355 � � 12,413 � Total assets $ 32,960,452 � $ 35,217,214 �
Liabilities and stockholders' equity Current liabilities Current
portion of capital lease obligation $ 58,708 $ 85,378 Current
portion of long-term debt obligation - 214,955 Accounts payable
2,093,850 2,757,381 Accrued liabilities 4,367,025 3,627,277
Deferred credits � 2,268,262 � � 874,676 � Total current
liabilities 8,787,845 7,559,667 Long-term capital lease obligation
12,039 27,873 Long-term debt obligation 5,000,000 5,000,000
Deferred credits and other long term liabilities � 604,418 � �
554,418 � Total liabilities � 14,404,302 � � 13,141,958 �
Stockholders' equity: Preferred stock, par value $0.001, 5,000,000
shares authorized at March 31, 2007, no shares issued and
outstanding - - Common stock, par value $0.001, 100,000,000 shares
authorized, 10,022,254 and 9,911,546 shares issued and outstanding
10,250 9,912 Additional paid-in capital 32,926,183 31,585,762
Accumulated deficit � (14,380,283 ) � (9,520,418 ) Total
stockholders' equity � 18,556,150 � � 22,075,256 � Total
liabilities and stockholders' equity $ 32,960,452 � $ 35,217,214 �
Luna Innovations Incorporated Consolidated Statements of Cash Flows
� � Six months ended � June 30, 2007 � 2006 � � (unaudited) �
(unaudited) Cash flows used in operating activities Net loss $
(4,859,865 ) $ (4,810,251 ) Adjustments to reconcile net loss to
net cash used in operating activities: Depreciation and
amortization 892,838 502,401 Share-based compensation 1,096,555
761,282 Change in assets and liabilities: Accounts receivable
(766,573 ) 981,715 Inventory (491,325 ) - Other assets 56,721
(347,358 ) Accounts payable and accrued expenses 76,216 703,875
Deferred revenues 1,443,585 � (489,876 ) Net cash used in operating
activities (2,551,848 ) (2,698,212 ) Cash flows used in investing
activities Acquisition of property and equipment (1,171,747 )
(632,587 ) Intangible property costs (196,790 ) (197,300 ) Net cash
used in investing activities (1,368,537 ) (829,887 ) Cash flows
from financing activities Payments on debt obligations (214,955 ) -
Payments on capital lease obligations (42,504 ) (49,899 ) Proceeds
from issuance of common stock, net - 17,660,608 Proceeds from the
exercise of options and warrants 244,206 � 79,028 � Net cash used
in financing activities (13,253 ) 17,689,737 � Net change in cash
(3,933,638 ) 14,161,638 Cash - beginning of period 17,866,753 �
12,514,839 � Cash - end of period $ 13,933,115 � $ 26,676,477 �
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024